Ladies and gentlemen, thank you for standing by, and welcome to the 2020 Pacira BioSciences Earnings Conference Call. At this time all participant lines are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Susan Mesco, Head of Investor Relations. Ma'am, please go ahead.

Thank you, Tina, and good morning everyone. Welcome to today's conference call to discuss our fourth quarter and full year 2020 financial results. Joining me as speakers on today's call are Dave Stack, Chairman and Chief Executive Officer; and Charlie Reinhart, Chief Financial Officer. Additional members of the Pacira executive leadership team are also in the room for today's question-and-answer session. Before we begin, let me remind you that today's call will include forward-looking statements based on our current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties. For information concerning risk factors that could affect the company please refer to our filings with the SEC, which are available from the SEC, or our website. With that I will now turn the call over to Dave Stack.

Thank you, Susan. Good morning, everyone, and thank you for joining us. 2020 was a difficult year for people around the world. Like all of you, we enter 2021 with great hope that the vaccines developed by our industry colleagues will stem the tide of the global pandemic. COVID-19 has further escalated our nation's opioid crisis placing an even brighter spotlight on the tremendous need for opioid-sparing pain management to avoid this key gateway to addiction. A rising number of drug-related fatalities continue given the health, social and economic disruptions that are facing our country. Equally important is the pain that patients have had to endure due to COVID-related delays and necessary surgical procedures. Expedited recovery is even more critical than ever, and we are dedicating considerable resources to develop and implement EXPAREL-based enhanced recovery after surgery or ERAS protocols that are enabling earlier discharge and accelerating the migration of elective procedures to outpatient sites of care. I am both proud and delighted to report that during these challenging times, we quickly adapted to our customer needs to provide opioid-free pain relief in a virtual world. This translated into record revenues for 2020 despite ongoing geographic disruptions in care delivery. This success is really a testament to the Pacira team and their steadfast commitment to provide an opioid alternative to as many patients as possible and redefine the role of opioids as rescue medication while enabling elective surgery migration to outpatient care. As noted in today's press release, our 2020 revenues were our highest ever coming in at $430 million for 2021, despite COVID-related challenges. The overwhelming needs of the marketplace and the transformation underway in the Ambulatory Surgery care setting allowed EXPAREL average daily sales to return to year-over-year growth in June. Attractive growth continued throughout the remainder of 2020 and we see this trend continuing right into 2021. None of these numbers should come as a surprise as we have aimed to be as transparent as possible during these unprecedented times by reporting our preliminary monthly sales. While we feel incredibly bullish about our long-term business prospects and revenue opportunity, near-term uncertainties around COVID remain, which can impact our business on a variety of levels. To provide you with insight into intra-quarter trends, we will continue to share monthly sales until we have visibility necessary to reinstate guidance. Today we also reported $113 million in adjusted EBITDA for 2020. As we continue to grow our top line and improve our gross margin, we are in an extraordinarily strong position to deliver accelerating profitability while continuing to support our top and bottom line growth with appropriate investments in operating expense. The vision we laid out years ago that highlighted the transition from an inpatient surgery-based company to an outpatient anesthesia based company is translating elegantly into a powerful earnings story. This ongoing evolution of the marketplace is the direct result of EXPAREL-based ERAS protocols. The important changes underway in the surgical sites of care are redefining medical practice for lower non-opioid post-surgical pain control, leaving us very bullish on our long-term growth outlook. Turning now to a more detailed strategic review of the business. 2020 was highlighted by strong execution across two robust global growth strategies. First, expanding the use of EXPAREL and iovera for opioid-sparing pain management while enabling the migration of large, painful and profitable procedures to the Ambulatory Surgery Center and hospital outpatient department settings. Second, pursuing innovation by investing in our internally and externally sourced portfolio of non-opioid pain management and regenerative health solutions while simultaneously advancing partnerships and education designed to revolutionize medical practice through the best practice opioid-sparing ERAS protocols. I'll start with EXPAREL. With more than 8 million patients treated since launch, EXPAREL remains well positioned for long-term market leadership as the only long-acting local analgesic approved for infiltration field block and brachial plexus nerve block. In January, we completed a smooth transition with our partners at J&J. For the last several months, we've been rolling out additional customer-facing resources to help support the market's continuing shift towards anesthesia-driven regional pain management and the migration of procedures to outpatient sites of care. In fact, we believe the increased use of regional anesthesia is the most important driver of our business for 2021. In 2020 only 20% of anesthesia procedures used the regional approach. The field is poised for rapid expansion given advances in ultrasound guidance, newer techniques, and improved outcomes. We are paving the way for EXPAREL to revolutionize the practice of regional anesthesia through our expanding networks of anesthesia group partnerships and robust educational and training initiatives. This is the key to the future and the focus of our state-of-the-art training center in Tampa, the PITT. For decades, anesthesiologists have had a high level of interest in regional blocks, but with short-acting agents only providing hours of pain control, it was difficult to justify a time return on investment. Fast forward to today; long-acting EXPAREL-based blocks have extended the duration of pain control to several days, allowing the EXPAREL block to be administered before patients arrive in the OR, truly a significantly positive change in the paradigm of patient care. Our anesthesia customers see the strong advantages of giving blocks and replacing antiquated pumps and catheters. Additionally, the ASC environment is an area where EXPAREL reimbursement is consistently improving as payers and self-insured employers continue to drive the shift from inpatient to outpatient care given the economic benefits. This is especially important for elective surgeries. Not only are these market dynamics fundamental to our growth, but they also directly correlate to patient outcomes and satisfaction rates given the compelling advantages of opioid-sparing regional approaches. I would like to highlight a few markets where we see continuing regional anesthesia redefine best practice for post-surgical pain control. EXPAREL administered as a brachial plexus nerve block continues to be a massive commercial opportunity. To remind you, an EXPAREL brachial plexus block provides coverage for the upper quadrant. So not only the rotator cuff and shoulder arthroplasty, but also elbow risks and hand procedures. We see the brachial plexus nerve block as an addressable market of more than 3 million patients per year. Our customers are consistently reporting positive results. Surgeons are not only delighted with clinical outcomes, but they also prefer the demonstrated consistent results of anesthesiologists administering single injection blocks preoperatively versus infiltration at the end of the case. After having success in brachial plexus blocks, anesthesiologists can broaden their use to a whole range of long-acting EXPAREL regional field and nerve blocks. Transverse abdominis or TAP blocks are a significant market where EXPAREL provides long-acting pain control for the abdominal region. As EXPAREL TAP block opens the door for more than $6 million abdominal and colorectal procedures per year and supports the migration of these painful procedures to the ASC space. There is a growing body of evidence supporting the safety and efficacy of TAP blocks with only a single high -- with only high single-digit penetration, and a surge of interest, we expect this market to be a significant long-term growth pillar. Turning to women's health, we are also seeing a strong uptick in the regional blocks for a variety of surgeries where EXPAREL is transforming the standard of care for women and enabling earlier discharge. Our Phase 4 data created great interest in establishing EXPAREL based TAP blocks as institutional protocol in cesarean section, gynecologic oncology, and abdominoplasty procedures. There is also growing utilization of pectoralis or PECs blocks for mastectomy and breast reconstruction and migrating these procedures to outpatient care. We are seeing significant demand among women for non-opioid pain control. Opioid addiction in women is growing at an alarming rate, with women 40% more likely to become newly persistent users of opioids following surgery. There are just under 4 million gynecologic oncology, C-section, and breast procedures each year in the United States. Women's health is a major opportunity that we remain in the infancy of tapping. We are also seeing the emergence of newer regional blocks driving significant demand in the market for information and training - excuse me, with details live and virtual programs taking place regularly at the PITT, our innovation and training facility in Tampa. Erector spinae or ESP block is another field block technique that is expanding a safe and effective approach for providing non-opioid pain control that expands from the bottom of the neck to the hip. This versatile block, which is relatively easy to perform, is growing in popularity for spine, scoliosis, and cardiothoracic procedures. A significant transformation is underway in the spine market. Historically, spine surgeries were largely confined to the inpatient setting with only a small percentage performed at outpatient sites of care. With the emergence of safe and effective blocks and opioid-sparing ERAS protocols, spinal procedures are on a trajectory like other painful orthopedic procedures with the rising number of ASCs specializing in these complex surgeries. With EXPAREL representing less than 2% of the total cost of the spine surgery case and 2.8 million procedures each year, this market is poised to be a key long-term revenue driver. In the cardiothoracic market, we have a growing single-digit penetration with 1.5 million procedures per year. There is great interest in making sure these patients do not leave the hospital relying on opioids to manage pain. Further, based on package inserts for other long-acting local analgesics, we believe EXPAREL has a clear safety advantage, especially for cardiac patients. The Pericapsular Nerve Group or PENG block is a newer regional technique that targets the anterior hip capsule. The PENG block is garnering great interest as it offers anesthesiologists and surgeons a means of shifting hip replacements for the outpatient setting. This is especially important since CMS has added total hip arthroplasty procedures to the ASC covered list effective January 1, 2021, joining knee arthroplasty which was added in January of 2020. Beyond the significant on-label opportunities I just highlighted, we are working to further broaden the EXPAREL label with key milestones on the near-term horizon. As you know, the FDA is reviewing our supplemental new drug application seeking approval for EXPAREL in patients aged 6 and older. The PDUFA action date is set for March 22. Having pediatrics on the label is of critical importance given the significant unmet need for non-opioid options for managing post-surgical pain in this vulnerable patient population. With approximately 1 million pediatric patients per year, catheters, and pumps are currently the mainstay of post-surgical pain control, we see a significant unmet need and envision this to be a minimum of a $100 million opportunity. Beyond pediatrics, we are also advancing our Phase 3 STRIDE study to evaluate EXPAREL versus bupivacaine as a nerve block for lower extremity procedures. We anticipate completion of enrollment by the end of the first quarter, with the clinical study report in the second quarter, and if successful, an approval in the second quarter of 2022. We believe the lower extremity opportunity to be as significant as the upper extremity market. We also continue to make progress in markets outside the United States. We remain on track to launch EXPAREL along with iovera in Europe in the middle of this year. Importantly, our broad efficacy label, which covers EXPAREL administration via infiltration field blocks and importantly both upper and lower extremity nerve blocks along with the superior safety profile, gives us a clear competitive advantage in Europe where iovera is already approved. For Canada, we remain in labeling discussions with health authorities. Given the current status, it is not likely we will launch in Canada as we will not jeopardize the brand with labeling that is not in harmony with major country regulatory authorities. In China, we are working with our partners to determine possible next steps in the regulatory process to provide EXPAREL to this market without any potential for proprietary data to be used to develop a generic. Before turning over to iovera, I would like to quickly touch on the market exclusivity for EXPAREL. Our own books Orange book listed patent expires later this year, and we have several unpublished and pending patents around the product process and manufacturing that we are confident will extend our proprietary position well into the '2040s. Remember, Pacira is the only company that is ever manufactured multivesicular liposomes at commercial scale anywhere in the world. Our sterile cold chain manufacturing facility would then require an operational license and validation prior to any bioequivalence study requirements by the FDA. This is a long and extensive process with little chance of duplicating the EXPAREL pharmacokinetic profile. Since we have never disclosed our proprietary batch specifications or release assay, in short, we have great confidence that there will never be a generic EXPAREL, and based on the package insert that we have seen for potential competitors, EXPAREL will remain the branded market leader for many years to come given our broad label, excellent safety profile, and flexible product features and benefits. Switching gears to iovera. Our innovative system, which delivers a non-pharmacologic nerve block using the body's natural response to cold to safely and immediately reduce pain. COVID-19 made 2020 a very difficult year for iovera and triggered significant clinical and commercial delays. While it's proving more difficult to achieve our initial objectives for iovera, we have implemented several commercial enhancements that we believe will start to take hold in 2021. We recently established a high-caliber management team of roughly 30 sales managers that will be dedicated to iovera, focusing on two specific opportunities. One is the procedural solution of iovera plus EXPAREL to improve total knee arthroplasty during before and after surgery. The second is iovera for opioid-free surgeries and drug-free osteoarthritis pain control. Simply put, if somebody is not ready for surgery or is not a surgical candidate for some reason, we can turn the pain signal off for several months with a simple 20-minute procedure. This allows them to play golf, walk on the beach, or enjoy family occasions such as a wedding or vacation. All the things that folks might not be able to do with significant osteoarthritis pain. On the clinical front, our prepared trial is enrolling patients to evaluate iovera and EXPAREL for opioid-sparing pain management for patients undergoing total knee arthroplasty. We expect enrollment to move before the end of this year. In parallel, we are launching an iovera registry to capture real-world experience for the use of TKA procedures with leading academic and orthopedic centers of excellence. We are also encouraged by the excitement around using iovera for other key areas. Key opinion leaders in orthopedics, spine, and anesthesia are interested in replacing heat-based radio frequency ablation with iovera cold therapy. We are seeing great interest across a wide range of treatment opportunities such as low back pain, spine spasticity, and rib fracture, and we will use investigator-initiated studies and grants to develop data across these areas. To remind you, iovera reimbursement in the hospital outpatient department setting is highly favorable with Medicare paying $900 to $1900 for iovera procedures targeting nerves around the knee. We continue to work to further enhance reimbursement to expand patient access to iovera. Our team of reimbursement specialists are experts in the space and working to maximize fee schedules for the value provided. We are also interacting with commercial payers to understand the economic advantages and improve patient outcomes associated with low or no opioid strategies. In summary, we remain highly confident in the technology behind the innovative system with sales potential approaching $200 million within our five-year planning horizon. Turning now to business development. Our team is leading a robust effort and thoughtfully pursuing opportunities of interest to surgical and anesthesia audiences we are calling out today. We believe our leadership position in opioid-sparing pain control provides us with a significant opportunity to build a differentiated portfolio to improve the patient journey along the neural pain pathway. We recently announced a strategic investment in GeneQuine. This transaction provides us the opportunity to participate in the development of an exciting disease-modifying gene therapy for osteoarthritis. GeneQuine's lead product candidate GQ-303 is currently in preclinical development as a treatment for osteoarthritis. GQ-303 is helper-dependent adenovirus vectors expressed PRT-4, a protein that plays an important role in regulating joint lubrication and decreasing inflammation. Finally, let's touch on some of our internally sourced non-opioid opportunities for acute and chronic pain. To augment our business development efforts, our in-house team is focusing on leveraging the proven safety, flexibility, and customizability of our DepoFoam platform. Our lead program is an epidural delivery of DepoFoam-based local anesthetic for acute and chronic pain. We are conducting a Phase 1 pilot study with EXPAREL, which will allow us to make a go/no-go decision in the next phase of development. We are also looking to add different DepoFoam opportunities to target inflammation and chronic pain. We look forward to keeping you apprised of our progress on this early-stage pipeline. And with that, I'd like to turn the call over to Charlie for a review of the financials.

Thank you, Dave, and good morning, everyone. Before discussing our fourth quarter financial results, I'd like to remind you that I'll be discussing non-GAAP financial measures this morning, which we believe more accurately reflect our business results. A description of these metrics along with our reconciliation to GAAP can be found in the press release we issued this morning. I would like to begin by reinforcing Dave's statement. We remain very bullish on the outlook for our business. Market indicators are strong with EXPAREL continuing to outperform the elective surgery market leaving us on track for accelerating top and bottom line growth as widespread deployment of the COVID-19 vaccines will further support the recovery and growth of elective surgery volumes. The COVID-19 pandemic has also acted as a catalyst for accelerating the shift of many procedures to outpatient settings where we remain ideally positioned to serve patients. We ended 2020 with more than $617 million of cash and investments. This strong foundation, along with our ability to generate high levels of operating cash flow, leaves us well equipped to continue to invest in internal and external growth opportunities that align with our mission. Fourth quarter total revenues of $131 million, or approximately 107% of total revenues for the fourth quarter of 2019, are our highest quarter ever despite the ongoing pandemic-related challenges. Fourth quarter net product sales of EXPAREL were $125.3 million, which was approximately 107% for the fourth quarter of 2019. For iovera, we reported net product sales of $2.4 million for the fourth quarter of 2020, down 25% from the $3.2 million for the fourth quarter of 2019 due to COVID-related commercial challenges. Our non-GAAP gross margin for the fourth quarter of 2020 was 74% versus 75% for the fourth quarter of 2019. Our investment in the expansion of manufacturing capacity in San Diego to include a 200-liter batch process suite was the primary driver of this change. Non-GAAP research and development expenses were $14.1 million in the fourth quarter of 2020 versus $18.3 million in 2019. The reduction is primarily driven by the capitalization of expenditures on our Swindon-based 200-liter manufacturing suite as we transition from the development phase to the registration phase. Non-GAAP SG&A expenses were $44.7 million for the fourth quarter of 2020 versus $47.6 million in 2019. The reduction is primarily attributable to decreased sales commissions to DePuy Synthes, which are directly linked to year-over-year EXPAREL growth, as well as the use of lower-cost virtual tools and the cancellation of in-person meetings, medical conferences, and non-essential travel during the COVID-19 pandemic. To remind you, our agreement with DePuy Synthes concluded in January 2021. All of this resulted in non-GAAP adjusted EBITDA of $42.9 million for the fourth quarter of 2020 versus $29.1 million in the fourth quarter of 2019. As Dave mentioned earlier, we are committed to reporting preliminary monthly product sales until we have the visibility necessary to fully reinstate financial guidance. With respect to taxes, beginning in the first quarter of 2021, our P&L will reflect a federal and state income tax provision, using an estimated combined rate of 25%. We continue to expect to become a cash taxpayer during the second half of 2022. Lastly, our long-term expectations for robust top and bottom line growth remain very bullish, and we believe that by the end of our five-year planning period, revenues will be approaching $1 billion for EXPAREL and $200 million for iovera. Gross margins will have improved to 1,000 basis points and operating margins will exceed 50% for our current base business. With that financial review, let me turn the call back to Dave for his closing remarks.

Thank you, Charlie. As 2021 unfolds, we begin to gain control over the COVID-19 pandemic through vaccines and new treatment options. Like all of you, we are looking forward to the world returning to a sense of normalcy. Despite the challenges we have faced with COVID-19 throughout 2020, we solidified our leadership role in non-opioid pain management by expanding the use of EXPAREL and its critical role in accelerating recovery and enabling transition of surgeries to the 23-hour setting. Weekly elective surgery data from IQVIA, which we have summarized in our investor presentations available on our website, continues to show EXPAREL consistently and significantly outperforming the market. These trends leave us very well positioned for more robust growth as the elective procedures normalize. We expect a very exciting 2021 as we build on the progress made in 2020 and further entrench EXPAREL as a leader in non-opioid post-surgical pain management and iovera in several orthopedic settings, achieving a number of value-creating milestones through additional strategic investments and collaborations. We entered the new year with a stronger position than ever to advance our mission of providing an opioid alternative to as many patients as possible using multimodal ERAS protocols and shifting opioids to the rescue-only scenario. With that, I'll turn the call over to Tina to begin our Q&A session.

Operator Instructions] And our first question is from Randall Stanicky with RBC Capital Markets.

Great. Thanks. Stack, just to go back to your last comment, and there is a lot of focus on the reopen right now. How does that impact Pacira? I'm really thinking about the opportunity for a volume boost for EXPAREL. Is that a 5%, 10% boost? And when do you think that first flow in? And then on the other end of that, we've talked a lot about the move to the ambulatory and outpatient setting. I think you're now in a low to mid 60% range. Does any of that gets pulled back into the hospital as the reopen takes place? And then my second question, just curious if you can comment on your view of the stickiness of your revenue and volume base ahead of what could be another competitor coming into the surgical pain area over the next several months? Thanks.

Thanks, Randall. First on the reopening, I think our message is pretty consistent and what's rolling out is pretty much what we thought was going to happen so far in 2021. I mean, our forecast for this year is that the first quarter would look pretty much like the last two or three quarters relative to growth versus the year before. I think it's fair to say that the impact of weather over the last couple of weeks especially is an added complication to getting these elective surgeries done, but I think generally what we thought was going to happen is that the first quarter would look a lot like last year with modest growth. We would start to see these surgical procedures come back out in Q2 and that we would see that accelerate pretty aggressively into Q3 and Q4. And based on the information we have in hand today, I don't see that there's any real reason to change that. So, we're pretty consistent with that these 4 million procedures that we think our warehouse, then the elective surgery total addressable market for Pacira will be an important growth factor in the second half of the year, but it's going to take us a little while yet to get there, and I don't see that changing in any meaningful way. The ASC question is an interesting one for us, and we don't see anything reversing in that area. In fact, quite the opposite. I mean, I think it's important for everybody to know that the people who own the environment of care now are not the providers. They are the payers. And the major payers, self-insured payers, and CMS are all aggressively moving patients to the ambulatory surgery market. So, I don't think that we'll see any removals back to the hospital. In fact, our patient surveys suggest that patients don't want to go back into a COVID environment are providers are increasingly aggressive about telling us that they have control over the environment and are more control over the environment in a surgical and an ASC they can actually have access to drugs like EXPAREL in different devices and things that's denied access in hospital settings. And interesting that when you talk to these guys, Randall, they would tell you I miss any of the kids' sporting events because I don't spend a half day rounding anymore like I did several years ago. So it's really been an aggressive move by the providers as well. And as I said earlier, the payers are in firm control of moving these procedures. And we had our national meeting last year and we had a little segment that I think, as meaningful to this growth, 5 years ago, you would have to get a prior authorization to have a Total knee arthroplasty and an Ambulatory Surgery Center. Today, you have to get a prior authorization to have a Total Knee arthroplasty in the hospital. And so it's come full circle, and I don't see that changing, in fact, we think it's going to continue to accelerate as elective surgeries come back out of the warehouse. And then the stickiness. I think we've seen the direct approval and it was a very - what would you say limited in terms of the indication with significant drawbacks in a black box warning. I don't think any of that changes going forward and where we are - as we've continue to follow or to develop our field blocks and nerve blocks, and we develop infiltration across a broad spectrum there is no reason to believe that anything that's in development is going to have a label it's even close to what is represented by EXPAREL today. And so we're very bullish about the future, and the competitors frankly I think will help accelerate our growth.

That's great. Thanks, Dave.

Your next question is from David Amsellem with Piper Sandler.

Thanks. So just a couple. First a question for - more for Charlie. I wanted to dig deeper into the extent to which you're going to have operating leverage and wanted to dig more deeply into the cost structure. How we should think about the trajectory of R&D and also sales and marketing spend, not just for this year but long term? And just give us a sense of how we should think about operating leverage and I guess also bundled into that question is also how we should think about gross margin expansion? So that's number one. And then secondly, can you talk about how the mix for EXPAREL is evolving among hospital, inpatient hospital outpatient, and ASCs. I know you've given some metrics in the past. Maybe talk about where you see the mix, particularly on the ASC front as the year progresses and also longer term? Thanks.

Thanks, David. Go ahead, Charles.

Sure. So let's just walk down the P&L from a gross margin perspective, David. We still expect gross margins to go from the mid '70s to the mid '80s and perhaps a little higher than that, frankly. That's going to be driven by two factors. One is the transition away from the 45-liter batch process to the 200-liter batch process, which includes from the UK perspective. And the other is volume, and so as because we believe volume will continue to expand and we expect those margins to follow suit based on both volume and the use of the 200-liter. The 200-liter in the UK should be operational end of this year, early next year, or at least not operational commercially available and ready to go. And so as that expands its contribution to total volumes, that will have an impact on margins. From an overall non-COGS OpEx perspective, the size of the R&D budget is not likely to go up much. Frankly, it depends on exactly what it is we're going to start investing that money in. So, the investment in EXPAREL is going to wind down. We've got a couple of interesting programs related to iovera that are on the schedule at this point, and we have a DepoFoam pipeline, and Ron Ellis is always bringing interesting things into the discussion point. So, we might expect to have some of that cash freed up for things that are already drawn the list of our pipeline at this point. So from an R&D perspective, we do not see any significant increases over the next three to five years, subject to any new BD opportunities coming online. From an SG&A perspective, G&A is going to go up very modestly. Sales and marketing will go up a little bit more, but we think when you average those two, you're talking about something in the low to mid-single-digit range. And so, if sales are going up in the high teens, and margins are going up from 75 to 85 and overall OpEx is going to go up somewhere in the low single digits, by definition, there is an awful lot of trust in the bottom line.

Okay. And answer your second question, David. So we now have August data. So it's at least six months behind. So, remember when we exited 2020, our 23-hour stay environment, our HOPD, and ASC was about 60% of the business in our TAM. And two things for this year. You see these markets growing, and so instead of having 32 million patients, or procedures in our TAM we now have 33.5 for 2021, so that bolsters a little bit. And as of August, we moved from 63% to -- from 60% to 63.5% of the procedures actually being done in the ambulatory surgery and hospital outpatient market. So in the middle of the pandemic, you saw a significant move on 32 million, a move of 3.5% is quite a lot in the middle of the pandemic. And so we see that as I've said a couple of times now increasing. It's almost entirely being driven by the opportunity to do a single administration nerve or field block that gives the pain and it is done under ultrasound guidance almost always now, and gives the clinicians the opportunity to have several days of pain control without a pump and a catheter, without having to use opioids. And remember in these markets, they don't have access to some of the things that would traditionally be used for large abdominal surgeries. For example, like a spinal like a thoracic epidural. So there are a number of drivers here that are moving patients to the ambulatory market, and in the ambulatory market, there are fewer options for how you treat pain. And so, we're almost in the perfect storm for us as we start to see these elective procedures come back out of the warehouse.

Got it. Thank you.

Thanks, Greg.

And we have time for one last question from Serge Belanger with Needham & Company.

Hi, good morning. Thanks for squeezing me in. Dave, my first question is about the traditional infiltration segments of the market. How big is that segment currently? How much of the external business is represented by that segment? Where do you think it's going? And then the second question. Can you just comment on the GeneQuine Biotherapeutics investment, maybe on the technology itself, and how the investment plays into your business development strategy?

Great. So I'm going to take the first half, and Ron Ellis our surgeon. I'm going to ask him to comment on the GeneQuine question. So first in terms of infiltration, we don't have a perfect data source, right. So we get data by procedure, by site of care and some of the data sets we can see who the provider is. But most of the time, we're actually looking at whether they used ultrasound or not and so we can sort of parse this out, but I want to be really clear with you that it is an imperfect multiple anecdote collaboration here that I'll tell you about. So, we think the current infiltration is about 30% of our business and it's, there are some places where it is the business, right. So there are certain areas where you wouldn't do a nerve block. For example, there are some ligatures that you don't want to do a nerve block and the shoulder of a professional athlete for example. And so infiltrations are still the standard of care and some of the market segments that we address. The PITT launch for example will be an infiltration launch. We are in discussions now with a nerve block label for PITTs, but that will be an infiltration launch. And probably the most significant is the multi-compartment opportunity. So if you do a TKA for example, we would do an adductor canal nerve block that would take care of the anterior of the knee largely, but you would still infiltrate the posterior capsule, and you would still infiltrate the periastron as part of a periarticular injection. So there's pieces of it that are never going to go away. And then there's pieces of it that are part of bigger procedures. So it's really hard for us to parse this out in a way, when I could be as specific as I would like to be with you and say 25.5%, I just don't know. What I can tell you is that it's a very small percentage of our growth. And so as we look forward, virtually everything that's allowing us to have the confidence that we're doing a field block or a nerve block that's going to last for three or four days and a patient that we're going to discharge after a significantly painful surgery in three or four hours are being done with some type of imaging by an anesthesiologist. And so, remember the surgeons don't get paid. When a surgeon does an infiltration at the end of the case, it's part of a bundle. When an anesthesiologist does this pre-going into the operating room it is outside the surgical bundle. So the anesthesiologists get paid, the surgeon doesn't get paid. The anesthesiologist does it before the patient goes in the OR, but the surgeon has to take a few minutes at the end of the case to do it in the OR, the surgeon still owns the patient again to be very candid, but it is not as hard as you think it might be to get the surgeon to ask the anesthesiologists to actually do a nerve block once they understand the ramifications of that, especially when they move him into the ASC. And Rob is going to talk to you about GeneQuine.

Seriously, appreciate the question on GeneQuine. In terms of the technology, I found it to be quite interesting. The gene therapy for Prg4 product, which is also known as Lubricant, there has been tense from the past to formulate the actual protein, but it's been challenging to do so. There may be some more recent breakthroughs in that space. Now, I think Dave has mentioned previously about how our partners in the field, the physicians themselves have spoken to us about what we have EXPAREL for surgery and as Dave just mentioned iovera for knee way before surgery, but can you help us earlier in that patient journey, and so this is our attempt to do so to partner with the providers and also be a partner with the patient, and help them in a non-opioid way get through this. And what we really see the promise in the gene therapy is not just the efficacy but also the duration of it that we can give something with similar efficacy to one's available today or better. And then also have that duration last.

Thank you.

Yeah. And that's very much in concert with what our Docs are looking for Serge. Most of the high-end guys in the pain space, the sports medicine space and the orthopedic space are looking at the world in more of a boutique kind of way where we want to have an earlier react or an earlier interaction with our patients, but it becomes almost a lifestyle, PRP and stem cells and lasers and all the other things that we're using for example, we're moving into that environment where - I mean the average age of a total knee arthroplasty in the United States last year was 59, right and 10 years ago, you would have gone a gel, right. And so it's changing very quickly, and we see that as an opportunity for us to operate with these guys and partnerships and establish how we're going to take care of these patients for 20 years instead of 2 hour surgical operations and that's the longer-term strategy here. So with that, I'm supposed to close. So I'd like to thank you all for participating and listening to today's conference call. We look forward to keeping you updated on our progress. Next up for us is the Barclays Conference in March. Thank you all, and stay well. Goodbye.

Thank you again for joining us today. This does conclude today's presentation. You may now disconnect.